Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gianni, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gianni, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:650-652, 2002
© 2002 European Society for Medical Oncology

Editorial

High-dose chemotherapy for breast cancer: any use for it?

L. Gianni

Director, Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy

The results of two studies of high-dose chemotherapy (HDCT) for the management of breast cancer appear in this issue of Annals of Oncology [1, 2]. The two reports come at a time when the field of HDCT for breast cancer appears in a protracted phase of very little appeal to doctors and patients alike. The very high expectations and excitement surrounding HDCT in the 1990s were countered by the preliminary results of large randomized studies showing that HDCT added only minor or no benefit to conventional-dose therapy [3–7]. In addition, the oncological community was set back by the shocking knowledge that the Bezwoda’s trials, reporting a therapeutic advantage from HDCT, were plagued by fabricated data [8, 9]. In such a scenario of minor or even bluntly negative consideration for the role of the HDCT approach, the articles appearing in this . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. M. Stemmer, S. Rizel, I. Hardan, A. Adamo, A. Neumann, J. Goffman, H. J. Brenner, and M. R. Pfeffer
The Role of Irradiation of the Internal Mammary Lymph Nodes in High-Risk Stage II to IIIA Breast Cancer Patients After High-Dose Chemotherapy: A Prospective Sequential Nonrandomized Study
J. Clin. Oncol., July 15, 2003; 21(14): 2713 - 2718.
[Abstract] [Full Text] [PDF]